Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $428,120.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Debra Durso-Bumpus sold 3,850 shares of Blueprint Medicines stock in a transaction on Friday, July 5th. The shares were sold at an average price of $111.20, for a total value of $428,120.00. Following the completion of the sale, the insider now directly owns 43,763 shares of the company’s stock, valued at approximately $4,866,445.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Debra Durso-Bumpus also recently made the following trade(s):

• On Wednesday, July 3rd, Debra Durso-Bumpus sold 8,817 shares of Blueprint Medicines stock. The shares were sold at an average price of $111.29, for a total value of $981,243.93.
• On Friday, June 28th, Debra Durso-Bumpus sold 333 shares of Blueprint Medicines stock. The stock was sold at an average price of $111.15, for a total transaction of $37,012.95.
• On Friday, June 21st, Debra Durso-Bumpus sold 74,034 shares of Blueprint Medicines stock. The shares were sold at an average price of $104.19, for a total transaction of $7,713,602.46.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC opened at $115.95 on Thursday. The business has a 50 day moving average price of $106.45 and a two-hundred day moving average price of $94.13. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $119.30. The firm has a market cap of $7.26 billion, a PE ratio of -24.11 and a beta of 0.63. The company has a quick ratio of 3.61, a current ratio of 3.76 and a debt-to-equity ratio of 0.67.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.32. The business had revenue of $96.12 million during the quarter, compared to analyst estimates of $82.58 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. Sell-side analysts expect that Blueprint Medicines Co. will post -5.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on BPMC shares. SVB Leerink raised shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and boosted their price objective for the company from $50.00 to $97.00 in a research note on Monday, May 6th. Citigroup boosted their price target on Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a research report on Friday, May 3rd. The Goldman Sachs Group raised their price objective on Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a report on Monday, May 6th. Oppenheimer boosted their target price on Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Leerink Partnrs raised shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating in a research report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $112.87.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors have recently modified their holdings of the stock. CWM LLC increased its holdings in Blueprint Medicines by 114.6% in the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 590 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Blueprint Medicines by 2.9% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 25,883 shares of the biotechnology company’s stock valued at $2,531,000 after acquiring an additional 733 shares in the last quarter. Comerica Bank lifted its stake in Blueprint Medicines by 2,582.9% during the first quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after purchasing an additional 10,435 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Blueprint Medicines in the first quarter worth $6,777,000. Finally, Kennedy Capital Management LLC bought a new stake in Blueprint Medicines during the first quarter valued at $220,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.